LysoPC(18:3(6Z,9Z,12Z))
|
Basic information |
| Metabolite name | LysoPC(18:3(6Z,9Z,12Z)) |
 | HMDB0010387 |
 |
C04230 |
 |
52924045 |
| Synonyms | LysoPC[18:3(6Z,9Z,12Z)] |
| No. of studies | 4 |
|
Basic information |
| Metabolite name | LysoPC(18:3(6Z,9Z,12Z)) |
| HMDB0010387 |
|
C04230 |
|
52924045 |
| Synonyms | LysoPC[18:3(6Z,9Z,12Z)] |
| No. of studies | 4 |
|
Relationship between LysoPC(18:3(6Z,9Z,12Z)) and depression (count: 4) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M210 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M210 | Type2 | CUMS + curcumin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M210 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M918 | Type1 | methamphetamine group vs. control group | Serum | C57BL/6 mouse | Up |